727 related articles for article (PubMed ID: 17180711)
1. The RANK/RANKL/OPG triad in cancer-induced bone diseases.
Dougall WC; Chaisson M
Cancer Metastasis Rev; 2006 Dec; 25(4):541-9. PubMed ID: 17180711
[TBL] [Abstract][Full Text] [Related]
2. RANKL signaling in bone physiology and cancer.
Dougall WC
Curr Opin Support Palliat Care; 2007 Dec; 1(4):317-22. PubMed ID: 18685382
[TBL] [Abstract][Full Text] [Related]
3. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
4. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
5. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
6. RANK ligand as a therapeutic target for bone metastases and multiple myeloma.
Roodman GD; Dougall WC
Cancer Treat Rev; 2008 Feb; 34(1):92-101. PubMed ID: 17964729
[TBL] [Abstract][Full Text] [Related]
7. Bone metastasis: can osteoclasts be excluded?
Martin TJ; Mundy GR
Nature; 2007 Feb; 445(7130):E19; discussion E19-20. PubMed ID: 17314931
[TBL] [Abstract][Full Text] [Related]
8. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton.
Mountzios G; Dimopoulos MA; Bamias A; Papadopoulos G; Kastritis E; Syrigos K; Pavlakis G; Terpos E
Acta Oncol; 2007; 46(2):221-9. PubMed ID: 17453373
[TBL] [Abstract][Full Text] [Related]
9. Key roles of the OPG-RANK-RANKL system in bone oncology.
Baud'huin M; Duplomb L; Ruiz Velasco C; Fortun Y; Heymann D; Padrines M
Expert Rev Anticancer Ther; 2007 Feb; 7(2):221-32. PubMed ID: 17288531
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
Dougall WC
Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
[TBL] [Abstract][Full Text] [Related]
11. [The OPG/RANKL/RANK system and bone resorptive disease].
Liu JZ; Ji ZL; Chen SM
Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
[TBL] [Abstract][Full Text] [Related]
12. Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.
Tanaka S
Am J Nephrol; 2007; 27(5):466-78. PubMed ID: 17652963
[TBL] [Abstract][Full Text] [Related]
13. OPG, RANK and RANK ligand expression in thyroid lesions.
Heymann MF; Riet A; Le Goff B; Battaglia S; Paineau J; Heymann D
Regul Pept; 2008 Jun; 148(1-3):46-53. PubMed ID: 18367263
[TBL] [Abstract][Full Text] [Related]
14. RANK/RANKL: regulators of immune responses and bone physiology.
Leibbrandt A; Penninger JM
Ann N Y Acad Sci; 2008 Nov; 1143():123-50. PubMed ID: 19076348
[TBL] [Abstract][Full Text] [Related]
15. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases.
Saad F; Markus R; Goessl C
BJU Int; 2008 May; 101(9):1071-5. PubMed ID: 18070191
[TBL] [Abstract][Full Text] [Related]
16. [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications].
Clézardin P
Bull Cancer; 2011 Jul; 98(7):837-46. PubMed ID: 21700551
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.
Blair JM; Zhou H; Seibel MJ; Dunstan CR
Nat Clin Pract Oncol; 2006 Jan; 3(1):41-9. PubMed ID: 16407878
[TBL] [Abstract][Full Text] [Related]
18. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
19. RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases.
Baud'huin M; Lamoureux F; Duplomb L; Rédini F; Heymann D
Cell Mol Life Sci; 2007 Sep; 64(18):2334-50. PubMed ID: 17530461
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors.
Fili S; Karalaki M; Schaller B
Cancer Lett; 2009 Sep; 283(1):10-9. PubMed ID: 19201081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]